Shopping Cart 0
Cart Subtotal
USD 0

Global Anti-Obesity Drugs Market Trends and Drivers, Restraints, and Opportunities 2017-2023

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2750

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 3500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 4500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Anti-obesity Drugs Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.

Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.

Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.

Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.

Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017-2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.

Types Analysis: The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.

Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.

Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.

Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.

Key Stakeholders:

 

 

READ MORE

Table Of Content

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Industry Trends 9

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 10

2.3 Research Methodology 11

2.4 Report Assumptions 12

3 Market Snapshot 12

3.1 Market Definition-Infoholic Research 12

3.2 Total Addressable Market 12

3.3 Segmented Addressable Market 13

3.4 Related Markets 14

3.4.1 Diabetes Drugs 14

3.4.2 Active Pharmaceutical Ingredients 15

3.4.3 Intragastric Balloon 15

3.4.4 Oncology (Cancer) Drugs 16

4 Market Outlook 16

4.1 Overview 16

4.2 Market Segmentation 17

4.3 Porter 5(Five) Forces 18

4.4 PEST Analysis 19

5 Market Characteristics 20

5.1 Market Evolution 20

5.2 Market Dynamics 21

5.2.1 Drivers 22

5.2.1.1 High prevalence of obesity 22

5.2.1.2 Unhealthy lifestyle 22

5.2.1.3 Chronic nature of obesity 23

5.2.2 Opportunities 23

5.2.2.1 Growing awareness of fitness 23

5.2.2.2 Large untapped market 23

5.2.3 Restraints 23

5.2.3.1 Side effects related to anti-obesity drugs 23

5.2.3.2 Availability of alternative treatment options 24

5.3 DRO-Impact Analysis 24

5.4 Key Stakeholders 25

6 Drug Details: Market Size and Analysis 26

6.1 Overview 26

6.2 Orlistat 27

6.3 Phentermine/Topiramate ER 27

6.4 Lorcaserin 28

6.5 Naltrexone SR/Bupropion SR 28

6.6 Liraglutide 3.0 mg 28

7 Types: Market Size and Analysis 29

7.1 Overview 29

7.2 Prescription Drugs (Rx) 29

7.3 OTC Drugs 30

8 Regions: Market Size and Analysis 31

8.1 Overview 31

8.2 North America 33

8.2.1 Overview 33

8.2.2 US 34

8.2.3 Canada 34

8.2.4 Mexico 34

8.3 Europe 35

8.3.1 Overview 35

8.3.2 UK 36

8.3.3 Germany 36

8.4 Asia Pacific 37

8.4.1 Overview 37

8.4.2 India 37

8.4.3 China 38

8.4.4 Australia 38

8.5 Rest of the World 38

8.5.1 Overview 38

8.5.2 Brazil 39

8.5.3 Africa 39

8.5.4 Middle East 39

9 Competitive Landscape 40

10 Vendors Profiles 42

10.1 F. Hoffmann-La Roche Ltd. 42

10.1.1 Overview 42

10.1.2 Business Units 45

10.1.3 Geographic Revenue 46

10.1.4 Business Focus 46

10.1.5 SWOT Analysis 47

10.1.6 Business Strategies 47

10.2 GlaxoSmithKline plc 48

10.2.1 Overview 48

10.2.2 Business Units 50

10.2.3 Geographic Revenue 51

10.2.4 Business Focus 52

10.2.5 SWOT Analysis 52

10.2.6 Business Strategies 53

10.3 Vivus, Inc. 53

10.3.1 Overview 53

10.3.2 Business Focus 55

10.3.3 SWOT Analysis 55

10.3.4 Business Strategies 56

10.4 Orexigen Therapeutics, Inc. 57

10.4.1 Overview 57

10.4.2 Business Focus 58

10.4.3 SWOT Analysis 59

10.4.4 Business Strategies 59

10.5 Eisai Co., Ltd. 59

10.5.1 Overview 59

10.5.2 Geographic Revenue 61

10.5.3 Business Focus 61

10.5.4 SWOT Analysis 61

10.5.5 Business Strategies 62

11 Companies to Watch for 62

11.1 Pfizer, Inc. 63

11.1.1 Overview 63

11.1.2 Highlights 64

11.2 Nova Nordisk A/S 64

11.2.1 Overview 64

11.2.2 Highlights 65

11.3 Boehringer Ingelheim GmbH 65

11.3.1 Overview 65

11.4 Rhythm Pharmaceuticals, Inc. 66

11.4.1 Overview 66

11.5 Zafgen, Inc. 67

11.5.1 Overview 67

11.6 Norgine B.V. 67

11.6.1 Overview 67

11.7 Merck & Co. 68

11.7.1 Overview 68

11.7.2 Highlights 69

11.8 Takeda Pharmaceutical Co., Ltd. 69

11.8.1 Overview 69

Annexure 70

Abbreviations 70

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ANTI-OBESITY DRUGS MARKET 11

CHART 2 GLOBAL ANTI-OBESITY DRUGS MARKET REVENUE, 2016-2023 (USD MILLION) 14

CHART 3 OBESITY-RELATED COST BY COUNTRY AS A PERCENTAGE OF TOTAL HEALTHCARE SPENDING (%) 17

CHART 4 SEGMENTATION OF GLOBAL ANTI-OBESITY DRUGS MARKET 17

CHART 5 PORTER 5 FORCES OF ANTI-OBESITY DRUGS MARKET 18

CHART 6 PEST ANALYSIS OF ANTI-OBESITY DRUGS MARKET 19

CHART 7 MARKET EVOLUTION 20

CHART 8 MARKET DYNAMICS-DRO ANALYSIS 21

CHART 9 DRO-IMPACT ANALYSIS OF GLOBAL ANTI-OBESITY DRUGS MARKET 24

CHART 10 KEY STAKEHOLDERS 25

CHART 11 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 (USD MILLION) 26

CHART 12 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 (USD MILLION) 29

CHART 13 PRESCRIPTION DRUGS (RX) MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 (USD MILLION) 30

CHART 14 OTC DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 (USD MILLION) 30

CHART 15 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2016 (%) 31

CHART 16 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2023 (%) 32

CHART 17 ANTI-OBESITY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2023 (USD MILLION) 33

CHART 18 EUROPEAN COUNTRIES' OBESITY RATE IN 2014 35

CHART 19 ANTI-OBESITY DRUGS MARKET REVENUE IN EUROPE, 2016-2023 (USD MILLION) 35

CHART 20 ANTI-OBESITY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2016-2023 (USD MILLION) 37

CHART 21 ANTI-OBESITY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2016-2023 (USD MILLION) 38

CHART 22 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 44

CHART 23 F. HOFFMANN-LA ROCHE: BUSINESS UNITS 45

CHART 24 F. HOFFMANN-LA ROCHE: GEOGRAPHIC REVENUE 46

CHART 25 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 47

CHART 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 49

CHART 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS 50

CHART 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE 51

CHART 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 52

CHART 30 VIVUS, INC.: OVERVIEW SNAPSHOT 54

CHART 31 VIVUS, INC.: SWOT ANALYSIS 55

CHART 32 OREXIGEN THERAPEUTICS, INC.: OVERVIEW SNAPSHOT 58

CHART 33 OREXIGEN THERAPEUTICS, INC.: SWOT ANALYSIS 59

CHART 34 EISAI CO., LTD.: OVERVIEW SNAPSHOT 60

CHART 35 EISAI CO., LTD.: GEOGRAPHIC REVENUE 61

CHART 36 EISAI CO., LTD.: SWOT ANALYSIS 61

 


List Of Table

Tables

TABLE 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS, 2016-2023 (USD MILLION) 32

TABLE 2 F. HOFFMANN-LA ROCHE: OFFERINGS 43

TABLE 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 43

TABLE 4 GLAXOSMITHKLINE PLC: OFFERINGS 48

TABLE 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 48

TABLE 6 VIVUS, INC.: OFFERINGS 54

TABLE 7 VIVUS, INC.: RECENT DEVELOPMENTS 54

TABLE 8 OREXIGEN THERAPEUTICS, INC.: OFFERINGS 57

TABLE 9 OREXIGEN THERAPEUTICS, INC.: RECENT DEVELOPMENTS 57

TABLE 10 EISAI CO., LTD.: OFFERINGS 60

TABLE 11 EISAI CO., LTD.: RECENT DEVELOPMENTS 60

TABLE 12 PFIZER: RECENT DEVELOPMENTS 63

TABLE 13 NOVO NORDISK: OVERVIEW 64

TABLE 14 NOVO NORDISK: RECENT DEVELOPMENTS 65

TABLE 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW 65

TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 66

TABLE 17 RHYTHM PHARMACEUTICALS, INC.: OVERVIEW 66

TABLE 18 RHYTHM PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS 66

TABLE 19 ZAFGEN: OVERVIEW 67

TABLE 20 NORGINE B.V.: OVERVIEW 67

TABLE 21 MERCK & CO.: OVERVIEW 68

TABLE 22 MERCK & CO.: RECENT DEVELOPMENTS 68

TABLE 23 TAKEDA PHARMACEUTICAL CO., LTD.: OVERVIEW 69

TABLE 24 TAKEDA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69

 

Licence Rights

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors

Anti-obesity Drugs Market-Global Drivers, Restraints, Opportunities, Trends, and Forecasts: 2017-2023

Overview: Globally, obesity has nearly tripled since 1975. In 2016, more than 1.9 billion adults, who were 18 years and older were overweight. Of these over 650 million were obese. An obese individual is at a higher risk of developing chronic diseases such as breast cancer, endometrial cancer, colon cancer, type 2 diabetes, cardiovascular diseases, and musculoskeletal disorders.

Anti-obesity drugs help in reducing body mass either by dipping the hunger or increasing the consumption of calories. The increasing prevalence of obesity globally is a major factor driving the market. It is principally because of wrong eating habits and swiftly varying regime of people. The increasing ingestion of unhealthy food along with the lack of exercises is intensifying the incidence rate of obesity globally.

Basic activities like reducing the intake of unhealthy diet and inculcating workout are not highly effective, and the medical devices like intragastric balloon and bariatric surgery are highly expensive and has high complications. This shows that there is a wide gap for the treatment of obesity. This unmet need is driving the market for anti-obesity drugs market.

Ill effects, such as the risk of mental illness, suicidal symptoms, stroke, are natively impacting the anti-obesity drugs market. Many drugs that were approved previously were withdrawn because of their side effects. Due to these factors healthcare specialists have an undesirable insight and do not recommend them to their clients.

Market Analysis: The Global Anti-Obesity Drugs Market is estimated to witness a CAGR of 20.9% during the forecast period 2017-2023. The market is analyzed based on three segments, namely top FDA approved drugs, types of anti-obesity drugs, and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (RoW). North America is the leading region for the anti-obesity drugs market growth followed by Europe. Asia Pacific and RoW are set to be the emerging regions. India and China are set to be the most attractive destinations due to the large untapped market.

Types Analysis: The top FDA approved anti-obesity drugs are Xenical, Saxenda, Contrave, Belviq, and Qsymia. Xenical was the largest selling drug in the market until 2012, but saw a dip in its revenue over the years. However, recently approved Saxenda by Novo Nordisk is gaining large interest among obese people and is growing at a fast growth rate.

Key Players: F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors.

Competitive Analysis: Novo Nordisk, an innovator of drugs in the obesity market, launched Saxenda in all the major markets with a higher dose of glucagon-like peptide-1 (GLP-1) receptor agonist, liraglutide, which was first launched for type 2 diabetes as Victoza. Dual therapy for obesity and type 2 diabetes is the latest trend in the market. Therefore, big pharmaceutical companies, such as AstraZeneca, J&J, and Sanofi, are adopting low-risk strategy of using diabetes drugs to treat the obesity related problem. This helps the diabetes market players to enter the obesity market. J&J is intended to enter the market for prescription anti-oobesity drugs without further investing in the development of novel molecules.

Benefits: The report provides complete details about the usage and adoption rate of anti-obesity drugs during the forecast period and the various regions. With that, the key stakeholders can know about the major trends, drivers, and investments, along with the details of the commercial drugs available in the market. Moreover, the report provides details about the major challenges that are going to impact the market growth. Additionally, the report gives complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in specific verticals to analyze before investing or expanding business in this market.

Key Stakeholders:

 

 

READ MORE

Scope

Table of Contents

1 Industry Outlook 9

1.1 Industry Overview 9

1.2 Industry Trends 9

2 Report Outline 10

2.1 Report Scope 10

2.2 Report Summary 10

2.3 Research Methodology 11

2.4 Report Assumptions 12

3 Market Snapshot 12

3.1 Market Definition-Infoholic Research 12

3.2 Total Addressable Market 12

3.3 Segmented Addressable Market 13

3.4 Related Markets 14

3.4.1 Diabetes Drugs 14

3.4.2 Active Pharmaceutical Ingredients 15

3.4.3 Intragastric Balloon 15

3.4.4 Oncology (Cancer) Drugs 16

4 Market Outlook 16

4.1 Overview 16

4.2 Market Segmentation 17

4.3 Porter 5(Five) Forces 18

4.4 PEST Analysis 19

5 Market Characteristics 20

5.1 Market Evolution 20

5.2 Market Dynamics 21

5.2.1 Drivers 22

5.2.1.1 High prevalence of obesity 22

5.2.1.2 Unhealthy lifestyle 22

5.2.1.3 Chronic nature of obesity 23

5.2.2 Opportunities 23

5.2.2.1 Growing awareness of fitness 23

5.2.2.2 Large untapped market 23

5.2.3 Restraints 23

5.2.3.1 Side effects related to anti-obesity drugs 23

5.2.3.2 Availability of alternative treatment options 24

5.3 DRO-Impact Analysis 24

5.4 Key Stakeholders 25

6 Drug Details: Market Size and Analysis 26

6.1 Overview 26

6.2 Orlistat 27

6.3 Phentermine/Topiramate ER 27

6.4 Lorcaserin 28

6.5 Naltrexone SR/Bupropion SR 28

6.6 Liraglutide 3.0 mg 28

7 Types: Market Size and Analysis 29

7.1 Overview 29

7.2 Prescription Drugs (Rx) 29

7.3 OTC Drugs 30

8 Regions: Market Size and Analysis 31

8.1 Overview 31

8.2 North America 33

8.2.1 Overview 33

8.2.2 US 34

8.2.3 Canada 34

8.2.4 Mexico 34

8.3 Europe 35

8.3.1 Overview 35

8.3.2 UK 36

8.3.3 Germany 36

8.4 Asia Pacific 37

8.4.1 Overview 37

8.4.2 India 37

8.4.3 China 38

8.4.4 Australia 38

8.5 Rest of the World 38

8.5.1 Overview 38

8.5.2 Brazil 39

8.5.3 Africa 39

8.5.4 Middle East 39

9 Competitive Landscape 40

10 Vendors Profiles 42

10.1 F. Hoffmann-La Roche Ltd. 42

10.1.1 Overview 42

10.1.2 Business Units 45

10.1.3 Geographic Revenue 46

10.1.4 Business Focus 46

10.1.5 SWOT Analysis 47

10.1.6 Business Strategies 47

10.2 GlaxoSmithKline plc 48

10.2.1 Overview 48

10.2.2 Business Units 50

10.2.3 Geographic Revenue 51

10.2.4 Business Focus 52

10.2.5 SWOT Analysis 52

10.2.6 Business Strategies 53

10.3 Vivus, Inc. 53

10.3.1 Overview 53

10.3.2 Business Focus 55

10.3.3 SWOT Analysis 55

10.3.4 Business Strategies 56

10.4 Orexigen Therapeutics, Inc. 57

10.4.1 Overview 57

10.4.2 Business Focus 58

10.4.3 SWOT Analysis 59

10.4.4 Business Strategies 59

10.5 Eisai Co., Ltd. 59

10.5.1 Overview 59

10.5.2 Geographic Revenue 61

10.5.3 Business Focus 61

10.5.4 SWOT Analysis 61

10.5.5 Business Strategies 62

11 Companies to Watch for 62

11.1 Pfizer, Inc. 63

11.1.1 Overview 63

11.1.2 Highlights 64

11.2 Nova Nordisk A/S 64

11.2.1 Overview 64

11.2.2 Highlights 65

11.3 Boehringer Ingelheim GmbH 65

11.3.1 Overview 65

11.4 Rhythm Pharmaceuticals, Inc. 66

11.4.1 Overview 66

11.5 Zafgen, Inc. 67

11.5.1 Overview 67

11.6 Norgine B.V. 67

11.6.1 Overview 67

11.7 Merck & Co. 68

11.7.1 Overview 68

11.7.2 Highlights 69

11.8 Takeda Pharmaceutical Co., Ltd. 69

11.8.1 Overview 69

Annexure 70

Abbreviations 70

 


List Of Figure

Charts

 

CHART 1 RESEARCH METHODOLOGY OF GLOBAL ANTI-OBESITY DRUGS MARKET 11

CHART 2 GLOBAL ANTI-OBESITY DRUGS MARKET REVENUE, 2016-2023 (USD MILLION) 14

CHART 3 OBESITY-RELATED COST BY COUNTRY AS A PERCENTAGE OF TOTAL HEALTHCARE SPENDING (%) 17

CHART 4 SEGMENTATION OF GLOBAL ANTI-OBESITY DRUGS MARKET 17

CHART 5 PORTER 5 FORCES OF ANTI-OBESITY DRUGS MARKET 18

CHART 6 PEST ANALYSIS OF ANTI-OBESITY DRUGS MARKET 19

CHART 7 MARKET EVOLUTION 20

CHART 8 MARKET DYNAMICS-DRO ANALYSIS 21

CHART 9 DRO-IMPACT ANALYSIS OF GLOBAL ANTI-OBESITY DRUGS MARKET 24

CHART 10 KEY STAKEHOLDERS 25

CHART 11 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 (USD MILLION) 26

CHART 12 ANTI-OBESITY DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016 (USD MILLION) 29

CHART 13 PRESCRIPTION DRUGS (RX) MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 (USD MILLION) 30

CHART 14 OTC DRUGS MARKET REVENUE BY TYPES SEGMENTATION, 2016-2023 (USD MILLION) 30

CHART 15 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2016 (%) 31

CHART 16 ANTI-OBESITY DRUGS MARKET SHARE BY REGIONAL SEGMENTATION, 2023 (%) 32

CHART 17 ANTI-OBESITY DRUGS MARKET REVENUE IN NORTH AMERICA, 2017-2023 (USD MILLION) 33

CHART 18 EUROPEAN COUNTRIES' OBESITY RATE IN 2014 35

CHART 19 ANTI-OBESITY DRUGS MARKET REVENUE IN EUROPE, 2016-2023 (USD MILLION) 35

CHART 20 ANTI-OBESITY DRUGS MARKET REVENUE IN ASIA PACIFIC, 2016-2023 (USD MILLION) 37

CHART 21 ANTI-OBESITY DRUGS MARKET REVENUE IN REST OF THE WORLD, 2016-2023 (USD MILLION) 38

CHART 22 F. HOFFMANN-LA ROCHE: OVERVIEW SNAPSHOT 44

CHART 23 F. HOFFMANN-LA ROCHE: BUSINESS UNITS 45

CHART 24 F. HOFFMANN-LA ROCHE: GEOGRAPHIC REVENUE 46

CHART 25 F. HOFFMANN-LA ROCHE: SWOT ANALYSIS 47

CHART 26 GLAXOSMITHKLINE PLC: OVERVIEW SNAPSHOT 49

CHART 27 GLAXOSMITHKLINE PLC: BUSINESS UNITS 50

CHART 28 GLAXOSMITHKLINE PLC: GEOGRAPHIC REVENUE 51

CHART 29 GLAXOSMITHKLINE PLC: SWOT ANALYSIS 52

CHART 30 VIVUS, INC.: OVERVIEW SNAPSHOT 54

CHART 31 VIVUS, INC.: SWOT ANALYSIS 55

CHART 32 OREXIGEN THERAPEUTICS, INC.: OVERVIEW SNAPSHOT 58

CHART 33 OREXIGEN THERAPEUTICS, INC.: SWOT ANALYSIS 59

CHART 34 EISAI CO., LTD.: OVERVIEW SNAPSHOT 60

CHART 35 EISAI CO., LTD.: GEOGRAPHIC REVENUE 61

CHART 36 EISAI CO., LTD.: SWOT ANALYSIS 61

 


List Of Table

Tables

TABLE 1 ANTI-OBESITY DRUGS MARKET REVENUE BY REGIONS, 2016-2023 (USD MILLION) 32

TABLE 2 F. HOFFMANN-LA ROCHE: OFFERINGS 43

TABLE 3 F. HOFFMANN-LA ROCHE: RECENT DEVELOPMENTS 43

TABLE 4 GLAXOSMITHKLINE PLC: OFFERINGS 48

TABLE 5 GLAXOSMITHKLINE PLC: RECENT DEVELOPMENTS 48

TABLE 6 VIVUS, INC.: OFFERINGS 54

TABLE 7 VIVUS, INC.: RECENT DEVELOPMENTS 54

TABLE 8 OREXIGEN THERAPEUTICS, INC.: OFFERINGS 57

TABLE 9 OREXIGEN THERAPEUTICS, INC.: RECENT DEVELOPMENTS 57

TABLE 10 EISAI CO., LTD.: OFFERINGS 60

TABLE 11 EISAI CO., LTD.: RECENT DEVELOPMENTS 60

TABLE 12 PFIZER: RECENT DEVELOPMENTS 63

TABLE 13 NOVO NORDISK: OVERVIEW 64

TABLE 14 NOVO NORDISK: RECENT DEVELOPMENTS 65

TABLE 15 BOEHRINGER INGELHEIM GMBH: OVERVIEW 65

TABLE 16 BOEHRINGER INGELHEIM GMBH: RECENT DEVELOPMENTS 66

TABLE 17 RHYTHM PHARMACEUTICALS, INC.: OVERVIEW 66

TABLE 18 RHYTHM PHARMACEUTICALS, INC.: RECENT DEVELOPMENTS 66

TABLE 19 ZAFGEN: OVERVIEW 67

TABLE 20 NORGINE B.V.: OVERVIEW 67

TABLE 21 MERCK & CO.: OVERVIEW 68

TABLE 22 MERCK & CO.: RECENT DEVELOPMENTS 68

TABLE 23 TAKEDA PHARMACEUTICAL CO., LTD.: OVERVIEW 69

TABLE 24 TAKEDA PHARMACEUTICAL CO., LTD.: RECENT DEVELOPMENTS 69

 

"Single User $3,500- PDF via email with only 1 user license terms or online access with login details to customer
- Multi Users $4,000- PDF via email with up to 10 user license terms
- Enterprise License $5,000- PDF via email, can be utilized across the organization and can upload in their intranet.
We do have the online access for our reports where client can utilize our knowledge store and they will have their login details to access the report online instead of PDF file."

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Companies

F. Hoffmann La Roche, GlaxoSmith Kline, Orexigen Therapeutics, Vivus Therapeutics, and Eisai Co, Ltd. are the key players in the market. Boehringer Ingelheim, Merck & Co, Nova Nordisk, Pfizer, Rhythm Pharmaceuticals, Zafgan, and Takeda Pharmaceuticals are the other prominent vendors